Biocryst Pharmaceuticals (BCRX) Change in Receivables (2010 - 2026)

Biocryst Pharmaceuticals' Change in Receivables history runs 17 years deep, the most recent figure standing at $474000.0 for Q1 2026.

• Quarterly Change in Receivables fell 96.61% year-over-year to $474000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (down 29.08% YoY) and the FY2025 annual result came in at $36.8 million, up 62.16% from the prior year.
• Change in Receivables was $474000.0 for Q1 2026 at Biocryst Pharmaceuticals, down from $15.5 million in the prior quarter.
• Across five years, Change in Receivables topped out at $15.5 million in Q4 2025 and bottomed at -$3.8 million in Q3 2023.
• A 5-year average of $5.1 million and a median of $5.3 million in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2022 — Change in Receivables surged 2600.38% — and 2023, when it slumped 358.96%.
• Biocryst Pharmaceuticals' Change in Receivables stood at $7.6 million in 2022, then tumbled by 61.14% to $3.0 million in 2023, then surged by 145.66% to $7.3 million in 2024, then surged by 112.36% to $15.5 million in 2025, then tumbled by 96.94% to $474000.0 in 2026.
• Business Quant data shows BCRX's Change in Receivables at $474000.0 in Q1 2026, $15.5 million in Q4 2025, and $17000.0 in Q3 2025.